Floatz logo

Cyclophosphamide

Intrahepatic Cholangiocarcinoma

TriSalus Life Sciences, Inc.Small moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Intrahepatic Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
Durvalumab
West China Hospital
Phase 2BB
Nivolumab
Virogin Biotech Canada Ltd
Phase 2BB
FILGRASTIM
Mayo Clinic
Phase 2B
Ipilimumab
TriSalus Life Sciences, Inc.
Phase 2B
Pembrolizumab
Shanghai 6th People's Hospital
Phase 1/2B

View all 20 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →